These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Thompson RH; Dong H; Kwon ED Clin Cancer Res; 2007 Jan; 13(2 Pt 2):709s-715s. PubMed ID: 17255298 [TBL] [Abstract][Full Text] [Related]
4. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Thompson RH; Webster WS; Cheville JC; Lohse CM; Dong H; Leibovich BC; Kuntz SM; Sengupta S; Kwon ED; Blute ML Urology; 2005 Nov; 66(5 Suppl):10-4. PubMed ID: 16194701 [TBL] [Abstract][Full Text] [Related]
5. Significance of B7-H1 overexpression in kidney cancer. Thompson RH; Kwon ED Clin Genitourin Cancer; 2006 Dec; 5(3):206-11. PubMed ID: 17239274 [TBL] [Abstract][Full Text] [Related]
6. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Krambeck AE; Thompson RH; Dong H; Lohse CM; Park ES; Kuntz SM; Leibovich BC; Blute ML; Cheville JC; Kwon ED Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10391-10396. PubMed ID: 16798883 [TBL] [Abstract][Full Text] [Related]
7. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Thompson RH; Dong H; Lohse CM; Leibovich BC; Blute ML; Cheville JC; Kwon ED Clin Cancer Res; 2007 Mar; 13(6):1757-61. PubMed ID: 17363529 [TBL] [Abstract][Full Text] [Related]
8. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Thompson RH; Kuntz SM; Leibovich BC; Dong H; Lohse CM; Webster WS; Sengupta S; Frank I; Parker AS; Zincke H; Blute ML; Sebo TJ; Cheville JC; Kwon ED Cancer Res; 2006 Apr; 66(7):3381-5. PubMed ID: 16585157 [TBL] [Abstract][Full Text] [Related]
9. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Krambeck AE; Dong H; Thompson RH; Kuntz SM; Lohse CM; Leibovich BC; Blute ML; Sebo TJ; Cheville JC; Parker AS; Kwon ED Clin Cancer Res; 2007 Mar; 13(6):1749-56. PubMed ID: 17363528 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Nakanishi J; Wada Y; Matsumoto K; Azuma M; Kikuchi K; Ueda S Cancer Immunol Immunother; 2007 Aug; 56(8):1173-82. PubMed ID: 17186290 [TBL] [Abstract][Full Text] [Related]
11. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. Quandt D; Jasinski-Bergner S; Müller U; Schulze B; Seliger B J Transl Med; 2014 May; 12():151. PubMed ID: 24885059 [TBL] [Abstract][Full Text] [Related]
13. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Ghebeh H; Mohammed S; Al-Omair A; Qattan A; Lehe C; Al-Qudaihi G; Elkum N; Alshabanah M; Bin Amer S; Tulbah A; Ajarim D; Al-Tweigeri T; Dermime S Neoplasia; 2006 Mar; 8(3):190-8. PubMed ID: 16611412 [TBL] [Abstract][Full Text] [Related]
15. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Konishi J; Yamazaki K; Azuma M; Kinoshita I; Dosaka-Akita H; Nishimura M Clin Cancer Res; 2004 Aug; 10(15):5094-100. PubMed ID: 15297412 [TBL] [Abstract][Full Text] [Related]
17. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation. Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700 [TBL] [Abstract][Full Text] [Related]
18. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. Webster WS; Thompson RH; Harris KJ; Frigola X; Kuntz S; Inman BA; Dong H J Immunol; 2007 Sep; 179(5):2860-9. PubMed ID: 17709500 [TBL] [Abstract][Full Text] [Related]
19. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751 [TBL] [Abstract][Full Text] [Related]
20. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]